De-identified health data means patient information that has had personal details like names, addresses, and social security numbers removed or hidden. This process helps protect patient privacy while allowing hospitals, researchers, and drug companies to study large sets of data for different uses. The removal of personal details follows strict rules, such as the HIPAA Safe Harbor Method in the U.S. and GDPR in Europe.
In 2024, the global market for de-identified health data was worth about USD 8.09 billion. Experts expect it to grow steadily at around 9.07% per year from 2025 to 2030. By 2030, it could reach USD 13.59 billion. North America leads this market, making up about 31.53% of the money earned in 2024. This is because it has advanced healthcare systems, strong privacy laws, and large investments in health technology and artificial intelligence.
A big reason the de-identified health data market is growing in the U.S. is due to more use of real-world evidence (RWE). RWE uses health information gathered outside of traditional clinical trials. This includes data from electronic health records, insurance claims, patient registries, and wearable devices. RWE gives a wider picture of how patients respond to treatments in everyday healthcare.
In 2024, the U.S. RWE market was valued at USD 909.4 million. It is expected to grow fast, reaching USD 4.1 billion by 2034, at a yearly rate of 16.3%. This growth is due to:
Drug companies and medical device makers are the main users of RWE, making up about 60.4% of the market in 2024. They use RWE to design better clinical trials, get faster approvals, and use their research money wisely.
Pharmaceutical companies lead in using de-identified health data for many reasons. In 2019 alone, they spent $83 billion on research and development in the U.S. They want clinical trials and drug development to be more efficient. De-identified data helps them:
Big companies like IQVIA, UnitedHealth Group (Optum), IBM, Flatiron Health, and Syneos Health hold about 85% of the U.S. RWE market. They combine different health data and use AI and machine learning to find useful information while keeping patient privacy.
Clinical research and trials use most of the de-identified health data and bring in the most revenue. Large sets of safe, private data help researchers create and test new treatments, watch for side effects, and predict how well treatments work.
In 2024, there are over 61,000 clinical studies registered worldwide, many recruiting patients from outside the U.S. This shows how research is global. These trials increasingly use tokenization. Tokenization is a method that hides patient ID details but links data from different sources to build a complete patient profile. By the end of 2024, Datavant had tokenized almost 270 clinical trials, growing nearly 300% since 2022.
Tokenization makes data better and deeper. It helps follow patients for a long time and reduces the need for patients to provide information repeatedly. This is especially important for rare diseases and personalized medicine, where fewer patients are involved and long-term data is needed.
Keeping patient data private and following rules is very important when working with de-identified health data. In the U.S., HIPAA sets strong rules on how data must be made anonymous to protect patient identity. The Safe Harbor Method lists specific details that must be removed so data can be used safely for research and analysis.
In Europe, GDPR has strict rules on processing and sharing data. It makes sure patient consent and privacy are considered carefully. These rules encourage healthcare providers and drug companies to use de-identified data that meets legal standards. This way, they keep public trust while using health data for research and improvements.
Artificial intelligence (AI), machine learning, and automation are playing bigger roles in handling and using de-identified health data. AI can quickly analyze large data sets, find patterns, and predict results. This supports research and helps with clinical decisions without risking patient privacy.
Companies like Philips and MIT’s Institute for Medical Engineering and Science have worked together to make AI tools using de-identified data from ICU patients. These tools improve support systems and patient care in intensive care units.
In clinical trials, firms such as ICON work with Intel to bring AI into trial steps. This helps with patient recruitment and makes data processes smoother. Their work supports real-time data checks, lowers administrative work, and helps with regulatory rules by automating data cleaning, anonymizing, and reporting.
Automation also helps health centers by improving data exchange through standards like HL7 FHIR APIs. This allows easy sharing of de-identified data in electronic health records. In 2024, the U.S. Department of Health and Human Services gave USD 56 million to update health centers’ tech, focusing on safe data collection and use. This money aims to improve healthcare quality by using better data and lowering reporting work.
Tokenization in clinical trials shows how automation helps by creating privacy-friendly IDs early in the data process. This lets sponsors monitor patients over time without extra effort and meet regulatory needs efficiently.
Medical practice administrators and IT managers in the U.S. see that data-driven decisions are becoming more important. The strength of the North American market shows many chances to invest in health IT, compliance programs, and AI tools.
Clinics and hospitals that provide data must follow HIPAA Safe Harbor rules while sharing data in ways that help research and public health. The rise of wearable health gadgets, remote sensors, and full electronic health record systems adds to the growing pool of de-identified data. This data can improve patient care and help with health plans for groups of people.
Investments are needed to train workers and improve infrastructure to handle these data resources well. Practices are likely to work more closely with drug companies and research groups, helping build large data networks that support clinical trials, better treatments, and health research.
Partnerships and company mergers keep shaping the industry. One example is the 2021 merger of Datavant and Ciox Health, which created the largest secure, neutral health data system in the U.S. This platform improves data sharing between different providers and supports clinical research.
Other partnerships, like nference working with Emory Healthcare, provide shared data networks that let researchers access data without showing patient details. These ties help with studies on disease diagnosis and treatment while protecting privacy.
In cancer care, companies such as Flatiron Health focus on creating real-world evidence from de-identified clinical data. This supports new cancer drug studies and helps with regulatory approvals. Drug companies using these platforms make trials more efficient and cut costs, bringing treatments to patients faster.
Important reasons for using de-identified health data include:
Still, healthcare groups face problems like a lack of common data formats and not enough skilled data scientists to work with complicated data. Bringing together data from electronic health records, wearable devices, and insurance claims needs strong technology and careful planning.
For medical practice administrators and IT managers in the U.S., staying updated on these changes is key to making good use of health data. Progress in de-identified data collection, AI-supported analysis, following rules, and industry teamwork is changing how health data helps research and patient care. Keeping up with these trends can help healthcare providers contribute to research while keeping data private and improving health results.
The global de-identified health data market was valued at USD 8.09 billion in 2024 and is projected to reach USD 13.59 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.07% from 2025 to 2030.
Growth is driven by rising demand for healthcare data, advancements in AI and machine learning, increasing adoption of healthcare analytics, expansion of Real-World Data (RWD) and Real-World Evidence (RWE), and regulatory incentives encouraging the use of privacy-compliant datasets.
North America dominated with a 31.53% revenue share in 2024, due to its advanced healthcare infrastructure, significant investments in health IT and AI, a strong pharmaceutical and biotech industry presence, and strict data privacy regulations like HIPAA promoting compliant data usage.
Clinical data holds the largest share (~17%) due to its essential role in research, treatment development, and patient care optimization. Epidemiological data is also growing rapidly due to public health initiatives focusing on disease tracking and prevention.
It is primarily applied in clinical research and trials, supporting treatment advancements and patient safety. Secondary applications include drug discovery, public health, precision medicine, health economics and outcomes research, and population health management.
Healthcare providers lead the market by using de-identified data for clinical decision-making, population health management, and quality improvement. Pharmaceutical companies are the fastest-growing end-users, leveraging data in drug development, clinical trials, and precision medicine.
Key frameworks include HIPAA in the U.S., which outlines data de-identification standards to protect patient privacy, and the GDPR in Europe, imposing strict regulations on data handling, consent, and privacy to ensure compliance globally.
Advancements in data analytics, AI, and machine learning enable extraction of insights from de-identified data while preserving privacy. Emerging methods like federated learning and synthetic data generation using large language models enhance data utility without compromising confidentiality.
Mergers like Datavant and Ciox Health created the largest secure U.S. health data ecosystem. Collaborations such as Philips with MIT, nference with Emory Healthcare, and ICON with Intel, focus on leveraging de-identified data to accelerate research, AI training, and clinical trial efficiency.
De-identification allows for secure data sharing across institutions, enabling AI systems to be trained on large datasets while protecting patient privacy. This supports advancements in diagnostics, personalized treatments, disease detection, and accelerates innovation in digital health technologies.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
